Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a phase 1b/2 study of combination 177Lu girentuximab + cabozantinib and ...

After hours: February 14 at 7:46:31 p.m. EST ...